Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs […]
The post AI drug development startup Pathos AI closes $237M investment appeared first on SiliconANGLE.
